Search

Your search keyword '"Cree, Bruce A. C."' showing total 543 results

Search Constraints

Start Over You searched for: Author "Cree, Bruce A. C." Remove constraint Author: "Cree, Bruce A. C."
543 results on '"Cree, Bruce A. C."'

Search Results

1. Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis

2. An autoantibody signature predictive for multiple sclerosis

4. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials

15. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis

16. Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.

17. B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity.

18. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

19. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial

20. Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.

23. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

28. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

30. High-resolution DNA methylation screening of the major histocompatibility complex in multiple sclerosis

32. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism

34. Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosis

40. Long-term Safety of Ozanimod in Relapsing Multiple Sclerosis and Moderately to Severely Active Ulcerative Colitis (P7-3.007)

41. Safety of the Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Patients With Relapsing Multiple Sclerosis (P7-3.013)

43. Accelerated Worsening in Serum Neurofilament Light Chain Levels and Multiple Sclerosis Functional Composite in Women with MS after Menopause (S9.009)

45. Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis (P5-3.010)

48. Effect of GBCA Use on Detection and Diagnostic Performance of the Central Vein Sign: Evaluation Using a 3-T FLAIR* Sequence in Patients With Suspected Multiple Sclerosis

50. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.

Catalog

Books, media, physical & digital resources